Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma By Ogkologos - April 27, 2026 47 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer MOST POPULAR Droplet Transmission vs. Airborne… What’s the difference? August 10, 2020 Autumn and Letting Go September 29, 2021 FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial... July 24, 2024 Supplemental Breast Cancer Imaging Techniques Could Lead to Earlier Detection of... May 28, 2025 Load more HOT NEWS Immunotherapy Combination Most Effective as Initial Treatment for BRAF+ Melanoma Medical Cannabis Formulation May Be Capable of Killing Breast Cancer Cells,... EMA Recommends Granting a Conditional Marketing Authorisation for Pralsetinib ESMO Asia Congress 2022, 2-4 December 2022
